GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOT) » Definitions » Common Stock

Biotech Acquisition Co (Biotech Acquisition Co) Common Stock : $231.30 Mil (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Biotech Acquisition Co Common Stock?

Biotech Acquisition Co's quarterly common stock increased from Mar. 2022 ($230.00 Mil) to Jun. 2022 ($230.28 Mil) and increased from Jun. 2022 ($230.28 Mil) to Sep. 2022 ($231.30 Mil).

Biotech Acquisition Co's annual common stock increased from . 20 ($0.00 Mil) to Dec. 2020 ($0.00 Mil) and increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($230.02 Mil).

Biotech Acquisition Co Common Stock Historical Data

The historical data trend for Biotech Acquisition Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotech Acquisition Co Common Stock Chart

Biotech Acquisition Co Annual Data
Trend Dec20 Dec21
Common Stock
- 230.02

Biotech Acquisition Co Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Common Stock Get a 7-Day Free Trial Premium Member Only 230.02 230.02 230.00 230.28 231.30

Biotech Acquisition Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Biotech Acquisition Co (Biotech Acquisition Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOT) » Definitions » Common Stock
Comparable Companies
HWKZ VLAT OSI PGSS LDHA LHAA VELO ZWRK IXAQ ITQ GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
545 West 25th Street, 20th Floor, New York, NY, USA, 10001
Website
Biotech Acquisition Co is a blank check company.
Executives
Albert F Hummel director, officer: Chief Investment Officer PO BOX 3407, RANCHO SANTA FE CA 92067
Biotech Sponsor Llc 10 percent owner 545 W. 25TH ST., 20TH FLOOR, NEW YORK NY 10001
Bruno Montanari director 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Ivan Jarry officer: Chief Operating Officer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Paul Bernard director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Aaron Kim director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Michael Schleifer director, 10 percent owner, officer: Chief Executive Officer 545 WEST 25TH STREET 20TH FLOOR, NEW YORK NY 10001
Thomas Fratacci officer: CFO & Treasurer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001

Biotech Acquisition Co (Biotech Acquisition Co) Headlines

From GuruFocus

Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination

By PRNewswire PRNewswire • 06-23-2022

Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination

By PRNewswire PRNewswire • 07-13-2022

Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination

By PRNewswire PRNewswire • 07-03-2022

Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity F

By PRNewswire PRNewswire • 07-08-2022

Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity F

By PRNewswire PRNewswire • 06-18-2022

Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity F

By PRNewswire PRNewswire • 05-29-2022

Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

By PRNewswire PRNewswire • 05-24-2022

Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

By PRNewswire PRNewswire • 06-13-2022

Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity F

By PRNewswire PRNewswire • 05-19-2022

Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment

By PRNewswire PRNewswire • 01-04-2023